A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice (AIRITY)

A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma - AIRITY

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030260133

Enrollment

3100

Registered

2026-05-27

Start date

2026-05-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma Bronchial asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Part 1 Age 6 years and older at the time of signing the consent Physician diagnosis of asthma for at least 12 months Existing treatment with low, medium, or high dose ICS and other asthma controllers as reflected in GINA steps 2 to 5 Participant or legally authorized representative (where applicable) has provided consent Part 2 Age 18 years and older at the time of signing the consent Physician diagnosis of asthma for at least 12 months Existing treatment with low or medium dose ICS and other asthma controllers as reflected in GINA steps 2 to 4 Participant or legally authorized representative (where applicable) has provided consent Participants must meet the criteria for at least one of the cohorts below Asthma Control Cohort 1 ACQ-5 greater than 1.5 2 ACQ-5 less than 1.5 Type 2 Biomarker Cohort 3 FeNO greater than or equal to 35 ppb and blood eosinophils greater than or equal to 300 cells per microliter 4 FeNO less than 35 ppb and blood eosinophils less than 300 cells per microliter

Exclusion criteria

Exclusion criteria: Current diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Participants with moderate/severe cognitive impairment. Participants with moderate/severe cardiac disease. Participants on immunosuppressive medication for a chronic condition. Participation in other interventional and non-interventional clinical study (currently or in the past 3 months).

Design outcomes

Primary

Measure	Time frame
Descriptive characterization of participants with asthma across severities based on physician and patient reported measures. Patient and Physician Reported Outcomes	—

Secondary

Measure	Time frame
Physician perspectives Participant perspectives Descriptive characteristics of participants with elevated neutrophils and EOS by medication (including biologics) use and treatment outcomes	—

Countries

Canada, China, France, Germany, Italy, Japan, Saudi Arabia, Spain, UAE, USA

Contacts

Public ContactTakashi Sato

Syneos Health Japan K.K.

Takashi.sato@syneoshealth.com+81-3-6700-4700

Outcome results